{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:14Z","timestamp":1791235334460,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.autrev.2022.103072","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T04:37:58Z","timestamp":1645591078000},"page":"103072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management"],"prefix":"10.1016","volume":"21","author":[{"given":"Marc","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Adedjouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Buob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Abisror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Planche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"De Seigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8867","key":"10.1016\/j.autrev.2022.103072_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0140-6736(93)91477-4","article-title":"The antiphospholipid syndrome: ten years on","volume":"342","author":"Hughes","year":"1993","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2022.103072_bb0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.autrev.2022.103072_bb0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.autrev.2022.103072_bb0020","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera","year":"2017","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.autrev.2022.103072_bb0025","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2022.103072_bb0030","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Prime"},{"issue":"20","key":"10.1016\/j.autrev.2022.103072_bb0035","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.161.20.2433","article-title":"Hypercoagulability syndromes","volume":"161","author":"Thomas","year":"2001","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.autrev.2022.103072_bb0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.autrev.2022.103072_bb0045","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/ard.2008.093179","article-title":"Euro-phospholipid project group (European forum on antiphospholipid antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients","volume":"68","author":"Cervera","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.autrev.2022.103072_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 1000 consecutive cases. EUROAPS study group","volume":"18","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.autrev.2022.103072_bb0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u00ab\u202fextra-criteria\u202f\u00bb manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2022.103072_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.autrev.2022.103072_bb0070","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103072_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/j.1538-7836.2005.01444.x","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","author":"Pengo","year":"2005","journal-title":"Thrombosis Haemostasis [Internet]"},{"issue":"2","key":"10.1016\/j.autrev.2022.103072_bb0080","article-title":"Renal involvement in antiphospholipid syndrome","volume":"16","author":"Pons-Estel","year":"2014","journal-title":"Curr Rheumatol Rep [Internet]"},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0085","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-019-04915-5","article-title":"Annexin-A5 resistance and non-criteria antibodies for the diagnosis of seronegative antiphospholipid syndrome","volume":"39","author":"Ferreira","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2022.103072_bb0090","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1136\/rmdopen-2020-001340","article-title":"Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study.; European forum on antiphospholipid antibodies","volume":"6","author":"Abisror","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2022.103072_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaim\u00e9","year":"2017","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients: clinical and immunologic manifestations of APS","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2022.103072_bb0105","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"12","author":"Nochy","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.autrev.2022.103072_bb0110","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0961203310397410","article-title":"Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"20","author":"Silvari\u00f1o","year":"2011","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.autrev.2022.103072_bb0115","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1440-1797.2007.00792.x","article-title":"Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies","volume":"12","author":"Cheunsuchon","year":"2007","journal-title":"Nephrology"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2022.103072_bb0120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J. Autoimmun."},{"issue":"2\u20133","key":"10.1016\/j.autrev.2022.103072_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12016-008-8112-z","article-title":"Renal involvement in the antiphospholipid syndrome (APS)\u2014APS nephropathy","volume":"36","author":"Tektonidou","year":"2009","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.autrev.2022.103072_bb0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.autrev.2022.103072_bb0135","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/ndt\/gfq356","article-title":"What nephrologists need to know about antiphospholipid syndrome","volume":"25","author":"Alchi","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.autrev.2022.103072_bb0140","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12016-010-8207-1","article-title":"Histopathology of lupus nephritis","volume":"40","author":"Giannakakis","year":"2011","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.autrev.2022.103072_bb0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/qjmed\/93.7.457","article-title":"The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury","volume":"93","author":"Griffiths","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2022.103072_bb0150","series-title":"The antiphospholipid syndrome","first-page":"89","article-title":"Pathology of the antiphospholipid syndrome","author":"Lie","year":"1996"},{"issue":"6","key":"10.1016\/j.autrev.2022.103072_bb0155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0272-6386(03)00352-4","article-title":"The expanding spectrum of renal diseases associated with antiphospholipid syndrome","volume":"41","author":"Fakhouri","year":"2003","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.autrev.2022.103072_bb0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrneph.2014.38","article-title":"Renal involvement in antiphospholipid syndrome","volume":"10","author":"Sciascia","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"issue":"10","key":"10.1016\/j.autrev.2022.103072_bb0170","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard.62.10.999","article-title":"Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension","volume":"62","author":"Sangle","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2022.103072_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4329\/wjr.v9.i1.10","article-title":"Impact of contrast-enhanced ultrasound in patients with renal function impairment","volume":"9","author":"Girometti","year":"2017","journal-title":"World J Radiol"},{"issue":"7","key":"10.1016\/j.autrev.2022.103072_bb0180","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ajem.2011.06.041","article-title":"Renal infarction in the ED: 10-year experience and review of the literature","volume":"30","author":"Antopolsky","year":"2012","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.autrev.2022.103072_bb0185","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2022.103072_bb0190","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.autrev.2022.103072_bb0195","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis","volume":"134","author":"M\u00fcller-Calleja","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0200","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2010-07-299099","article-title":"Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome","volume":"117","author":"Romay-Penabad","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.autrev.2022.103072_bb0205","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","author":"Seshan","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.autrev.2022.103072_bb0215","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1399-0012.2012.01625.x","article-title":"Ten-yr renal allograft survival of patients with antiphospholipid anti- body syndrome","volume":"26","author":"Vaidya","year":"2012","journal-title":"Clin. Transpl."},{"issue":"9","key":"10.1016\/j.autrev.2022.103072_bb0220","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1600-6143.2010.03233.x","article-title":"Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies","volume":"10","author":"Canaud","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.autrev.2022.103072_bb0225","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0272-6386(99)70009-0","article-title":"Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in96 consecutive patients with systemic lupus erythematosus","volume":"34","author":"Stone","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.autrev.2022.103072_bb0230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0041-1345(98)01629-7","article-title":"Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft","volume":"31","author":"Wagenknecht","year":"1999","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.autrev.2022.103072_bb0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00007890-199907270-00014","article-title":"Antiphospholipid antibodies are a risk factor for early renal allograft failure","volume":"68","author":"Wagenknecht","year":"1999","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0240","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ndt\/gfx353","article-title":"Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey","volume":"33","author":"Gauthier","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.autrev.2022.103072_bb0245","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ndt\/6.8.543","article-title":"Anticardiolipin antibodies and lupus anticoagulant in end-stage renal- disease","volume":"6","author":"Garciamartin","year":"1991","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.autrev.2022.103072_bb0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0003-4975(99)00458-0","article-title":"Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients","volume":"68","author":"Fastenau","year":"1999","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.autrev.2022.103072_bb0255","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0272-6386(12)80383-0","article-title":"Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies","volume":"23","author":"Prieto","year":"1994","journal-title":"Am. J. Kidney Dis."},{"issue":"10","key":"10.1016\/j.autrev.2022.103072_bb0260","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2022.103072_bb0265","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3389\/fimmu.2018.01181","article-title":"Antiphospholipid syndrome nephropathy: from pathogenesis to treatment","volume":"9","author":"Tektonidou","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2022.103072_bb0270","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","volume":"295","author":"Lim","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2022.103072_bb0275","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","article-title":"A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","volume":"57","author":"Ruiz-Irastorza","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.autrev.2022.103072_bb0280","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/joim.13022","article-title":"The antiphospholipid syndrome - often overlooked cause of vascular occlusions?","volume":"287","author":"Svenungsson","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.autrev.2022.103072_bb0285","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103072_bb0290","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1310\/hpj5109-759","article-title":"Role of novel oral anticoagulants in the treatment of antiphospholipid syndrome","volume":"51","author":"White","year":"2016","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.autrev.2022.103072_bb0295","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103072_bb0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2017.03.006","article-title":"Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban","volume":"153","author":"Crowley Maeve","year":"2017","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.autrev.2022.103072_bb0305","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1191\/0961203303lu461oa","article-title":"Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy","volume":"12","author":"Korkmaz","year":"2003","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.autrev.2022.103072_bb0310","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/0961203314538687","article-title":"Identification and treatment of APS renal involvement","volume":"23","author":"Tektonidou","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103072_bb0315","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0961203311400115","article-title":"Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome","volume":"20","author":"Sciascia","year":"2011","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.autrev.2022.103072_bb0320","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.autrev.2022.103072_bb0325","first-page":"215","article-title":"Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab","volume":"14","author":"Tsagalis","year":"2010","journal-title":"Hippokratia"},{"issue":"2","key":"10.1016\/j.autrev.2022.103072_bb0330","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"26","key":"10.1016\/j.autrev.2022.103072_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.autrev.2022.103072_bb0340","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"11","key":"10.1016\/j.autrev.2022.103072_bb0345","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/rheumatology\/key228","article-title":"Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review","volume":"57","author":"Guillot","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2022.103072_bb0350","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"15","author":"Kronbichler","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.autrev.2022.103072_bb0355","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2017.05.006","article-title":"Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. On the behalf of the SNFMI and the European forum on antiphospholipid antibodies","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2022.103072_bb0360","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2012.07.005","article-title":"Catastrophic antiphospholipid syndrome (CAPS)","volume":"26","author":"Sciascia","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2022.103072_bb0365","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients","volume":"5","author":"Sinico","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.autrev.2022.103072_bb0370","first-page":"2817","article-title":"Primary antiphospholipid syndrome: functional outcome after 10 years","volume":"27","author":"Erkan","year":"2000","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2022.103072_bb0375","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0961203310395051","article-title":"Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:22Z","timestamp":1761600382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1568997222000428"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103072","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103072"}}